17(R)-Resolvin D1

17(R)-Resolvin D1 (17R-RvD1) is a specialized pro-resolving mediator derived from omega-3 fatty acids that plays a key role in the resolution of inflammation. It is produced by the enzymatic conversion of docosahexaenoic acid (DHA) through a series of reactions involving lipoxygenases and epoxide hydrolases. 17R-RvD1 acts by interacting with specific receptors on immune cells and endothelial cells to promote the clearance of pathogens, debris, and apoptotic cells, while also minimizing tissue injury and promoting tissue repair. Research has shown that 17R-RvD1 has potent anti-inflammatory effects in a variety of experimental models of acute and chronic inflammation, including sepsis, asthma, and colitis. It has also been shown to be effective in promoting wound healing and tissue regeneration. 17R-RvD1 has been proposed as a potential therapeutic agent for a variety of inflammatory disorders, and several clinical trials are currently underway to evaluate its efficacy in humans. Chemically, 17R-RvD1 is a lipid molecule with a molecular weight of approximately 376.6 g/mol. It has a unique structure that includes a conjugated triene system and a hydroxyl group at the 17th position. The stereochemistry of the molecule is critical for its biological activity, with the 17(R) configuration being the most active. Overall, 17R-RvD1 represents an exciting new area of research in the field of inflammation and offers great promise as a therapeutic agent for a variety of inflammatory disorders.